AbstractCaffeine is the most frequently consumed stimulant worldwide and has been championed as an attentional enhancer in clinical trials for over a hundred
years. There is broad agreement that caffeine induces an attention enhancing
effect. However, a minority disagree and propose the caffeine withdrawal
reverse hypothesis. This posits that, due to inadequate caffeine withdrawal
procedures in study design, the beneficial properties displayed by caffeine on
attention result from reversal of caffeine withdrawal. In caffeine studies with an
appropriate withdrawal period prior to intervention, no clear beneficial effect on
attention has been demonstrated. This thesis critically appraised the literature
and using a novel experimental paradigm, explored the utility of caffeine as an
attentional enhancer in participant groups consisting of healthy elderly, dementia with Lewy bodies (DLB), Parkinson’s disease (PD) and multiple
sclerosis (MS) sufferers.
I conducted a blinded, randomised controlled, cross over design trial to explore whether caffeinate improved performance on experimental and real-world tasks of attention. I systematically assessed three broad areas of attention:
alerting, orienting and executive networks with neuropsychometry tasks aligned to each domain. These experiments are unique within the literature as they combine a complete caffeine withdrawal period prior to intervention, a
systematic approach to assessing for attentional enhancement and patient
cohorts not previously investigated in relation to the attentional effect of acute caffeine ingestion.
I conclude caffeine is not an effective attention enhancer, at least not in
populations of healthy older people or people with PD or DLB. The possibility
remains that caffeine may enhance attention in people with MS and perhaps in
other situations such as sleep deprivation.
|Date of Award||1 Oct 2019|
|Supervisor||Patrick Gavin Kehoe (Supervisor) & E J Coulthard (Supervisor)|